From: Douglas Campbell [drcampbell@engineer.com]
Sent: Monday, March 19, 2001 12:57 PM
To: fdadockets@oc.fda.gov
Subject: Docket No. 00D-1598

Docket No. 00D-1598

Voluntary labeling is completely unacceptable.

The Food & Drug Administration exists to protect the public health.  To permit food manufacturers to use genetically-altered ingredients without listing them on the label is to deny consumers the right to choose what they will eat.  Why should we be subjected to potential allergens or less-nourishing alternatives without our knowledge or consent?

The minimum acceptable level of consumer protection is MANDATORY labeling of all ingredients, including genetically altered and irradiated ones, and a moritorium on the use of such ingredients until such time as they have been affirmitively proven to be safe and carry the same nutritional content.


============================================================== 
  
 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
 
Food and Drug Administration 
 
[Docket No. 00D-1598] 
 
 
Draft Guidance for Industry: Voluntary Labeling Indicating 
    Whether Foods Have or Have Not Been Developed Using 
    Bioengineering; Availability 
 
AGENCY: Food and Drug Administration, HHS. 
 
ACTION: Notice. 
 
 
-------------------------------------------------------------- 
 
 
SUMMARY: The Food and Drug Administration (FDA (we)) is 
announcing the availability of a draft guidance for industry 
entitled "Voluntary Labeling Indicating Whether Foods Have or 
Have Not Been Developed Using Bioengineering."  FDA developed 
this draft guidance to assist manufacturers, who wish to 
voluntarily label their foods (human and animal) as being 
made with or without bioengineering or the use of 
bioengineered ingredients, to ensure that labeling is 
truthful and not misleading.  FDA is taking this action in 
response to requests from food manufacturers and as part of 
the Clinton administration's initiatives to strengthen 
science-based regulation of bioengineered foods and consumer 
access to information. 
 
DATES: Submit written comments concerning the draft guidance 
to ensure adequate consideration in the preparation of a 
revised guidance, if warranted, by March 19, 2001.
 
However, you may submit written comments at any time. 
Submit written comments concerning the collection of 
information by March 19, 2001. 
 
ADDRESSES: Submit written comments on the draft guidance and 
the collection of information to the 
 
    Dockets Management Branch (HFA-305) 
    Food and Drug Administration 
    5630 Fishers Lane, Rm. 1061 
    Rockville, MD  20852 
        [forwarder's note:  e-mail is fdadockets@oc.fda.gov] 
 
==============================================================
 - - -

Douglas Campbell
335 e. Lewiston
Ferndale, Michigan  48220-1356
42o 27' 51" N  -  83o 8' 1" W  -  645' MSL

Michigan PE 43850
DrCampbell@Engineer.com
(248) 542-5216   (voice)








































.

______________________________________________
FREE Personalized Email at Mail.com
Sign up at http://www.mail.com/?sr=signup